Abstract
The protozoan diseases leishmaniasis, Chagas' disease and African trypanosomiasis are major health problems in many countries, particularly developing countries, and there are few drugs available to treat these diseases. Dihydrofolate reductase (DHFR) inhibitors have been used successfully in the treatment of a number of other diseases such as cancer, malaria and bacterial infections; however they have not been used for the treatment of these diseases. This article summarises studies on leishmanial and trypanosomal DHFR inhibitor development and evaluation. Possible mechanisms of resistance to DHFR inhibitors are also discussed. (C) 2002 Elsevier Science B.V All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | 249-257 |
| Number of pages | 9 |
| Journal | BBA - Molecular Basis of Disease |
| Volume | 1587 |
| Issue number | 2-3 |
| DOIs | |
| Publication status | Published - 18 Jul 2002 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Inhibitors of dihydrofolate reductase in leishmania and trypanosomes'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver